The global financial advisory landscape for Healthcare Technology (HealthTech), Medical Technology (MedTech), and Healthcare Artificial Intelligence (AI) has entered a profound phase of structural realignment, recognised across institutional corporate finance as the "Great Rationalisation". Departing from the unconstrained, growth at all costs venture capital environment of the early 2020s, enterprise valuations across digital health are governed by clinical utility, regulato